Enanta director granted 20,000 stock options

Enanta Pharmaceuticals director Mark G. Foletta received a grant of stock options covering 20,000 shares of common stock.

Rhea-AI Filing Summary

Enanta Pharmaceuticals director Mark G. Foletta received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $14.17 per share, were granted at no cost, and expire on March 11, 2036.

The award vests monthly in substantially equal installments over one year, beginning on March 11, 2026, with the final installment vesting no later than the trading day before the 2027 annual stockholder meeting. Following this grant, Foletta holds options for 20,000 shares directly, reflecting routine equity-based director compensation rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider FOLETTA MARK G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 20,000 contracts (Direct)

Footnotes (1)

1. F1. Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Enanta (ENTA) director Mark G. Foletta report on this Form 4?

Director Mark G. Foletta reported receiving a grant of stock options for 20,000 Enanta common shares. The grant is a compensation-related award, not an open-market trade, and represents new derivative holdings directly owned by him following the transaction.

What are the key terms of the Enanta (ENTA) stock options granted to Mark G. Foletta?

The options cover 20,000 Enanta common shares at an exercise price of $14.17 per share and expire on March 11, 2036. They were granted at no cost as a compensation award to Foletta in his role as director.

How do the Enanta (ENTA) options granted to Mark G. Foletta vest?

The 20,000 options vest monthly in substantially equal installments over one year starting March 11, 2026. The final monthly installment will vest no later than the nearest Nasdaq trading day before Enanta’s 2027 annual stockholder meeting.

Does this Enanta (ENTA) Form 4 show Mark G. Foletta buying or selling shares in the market?

The filing does not show any open-market buying or selling. It reports a grant of 20,000 stock options as a compensation award, classified as an acquisition of derivative securities rather than a purchase or sale of existing common shares.

How many Enanta (ENTA) options does Mark G. Foletta hold after this transaction?

After this grant, Foletta directly holds stock options for 20,000 Enanta common shares. These options are subject to the stated vesting schedule and carry an exercise price of $14.17 per share with an expiration date of March 11, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOLETTA MARK G

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.17	03/11/2026		A		20,000		(1)	03/11/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

	/s/ Matthew Kowalsky as attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.